Skip to main content

Table 3 Infectious complication during the observation period

From: Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study

 

Control group (n = 56)

TCZ group (n = 8)

P

 At least one infectious complication

19 (33.9)

5 (62.5)

0.139

 Bacteremia

8 (14.3)

4 (50.0)

0.035

 Fungemia

5 (8.9)

3 (37.5)

0.054

 Pneumonia/lower-respiratory tract infection

10 (17.9)

1 (12.5)

1.000

 GI infection

4 (7.1)

0 (0.0)

1.000

 Other infections

3 (5.4)

0 (0.0)

1.000

 Infection of unknown focus

1 (1.8)

0 (0.0)

1.000

  1. GI, Gastrointestinal; TCZ, tocilizumab